RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Real-world assessment of clinical outcomes associated with immunotherapy (io) and chemotherapy in non-small cell lung cancer (NSCLC) patients with brain metastases and metexon14 skipping mutations treated in us community centers.
Cai, B., Egloff, S. A. A., Goyal, R. K., Cai, B., Caro, N., Frost, M., Mahmud, S., Ansquer, V. D., Davis, K. L., Brisbin, L., Lisi, M., McKenzie, A. J., & Paulson, S. (2023). Real-world assessment of clinical outcomes associated with immunotherapy (io) and chemotherapy in non-small cell lung cancer (NSCLC) patients with brain metastases and metexon14 skipping mutations treated in us community centers.Journal of Thoracic Oncology, 18(3), E37-E37.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.